<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04806594</url>
  </required_header>
  <id_info>
    <org_study_id>ReGl/19/PAS-Acn/001</org_study_id>
    <nct_id>NCT04806594</nct_id>
  </id_info>
  <brief_title>Clinical Investigation on the Safety and Clinical Performance of Papix Acne Scar.</brief_title>
  <official_title>Open Label, Uncontrolled Clinical Investigation on the Safety and Clinical Performance of Papix Acne Scar in the Prevention and Improvement of Scars and Lesions Associated With Acne</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Relife S.r.l.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Relife S.r.l.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The scope of this open label clinical trial is to evaluate and confirm the performance of&#xD;
      Papix acne scar in the prevention and improvement of acne scars in subject suffering for mild&#xD;
      to moderate acne. The product will be applied for 8 consecutive weeks and 3 clinical follow&#xD;
      up visits will be performed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The scope of this open label clinical trial is to evaluate and confirm the performance of&#xD;
      Papix acne scar in the prevention and improvement of acne scars in subject suffering for mild&#xD;
      to moderate acne. The product will be applied for 8 consecutive weeks, 2 times per day into&#xD;
      the face.&#xD;
&#xD;
      The dermatologist will perform 3 clinical follow up visits to assess the efficacy and safety&#xD;
      of the product.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Multicenter, open label, uncontrolled, single arm, post-market clinical follow-up study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate and confirm the performance of PAPIX ACNE SCAR in the prevention and improvement of scars in subject suffering for mild to moderate acne, after 4 weeks of treatment</measure>
    <time_frame>four weeks of treatment</time_frame>
    <description>Indicate the proportion of subjects with improved acne scars and marks respect to baseline and, at the same time, without any new facial acne scars after 4 weeks of treatment with the change in the qualitative Scar Global Assessment (SGA) questionnaire.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the performance of PAPIX ACNE SCAR in the prevention and improvement of scars after 2 and 8 weeks of treatment.</measure>
    <time_frame>two weeks of treatment and 8 weeks of treatment</time_frame>
    <description>Indicate the proportion of subjects with improved acne scars and marks with respect to baseline and, at the same time, without any new facial acne scars after 2 and 8 weeks of treatment. The improvement of acne scars and marks will be assessed as the change in the qualitative Scar Global Assessment (SGA) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the performance of PAPIX ACNE SCAR in the prevention of lesions after 2, 4 and 8 weeks of treatment</measure>
    <time_frame>two weeks, 4 weeks and 8 weeks of treatment</time_frame>
    <description>Indicate the prevention of acne lesions after 2, 4 and 8 weeks of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>evaluate acne severity</measure>
    <time_frame>two weeks, 4 weeks and 8 weeks of treatment</time_frame>
    <description>To evaluate acne severity after 2, 4 and 8 weeks of treatment, through the Investigator Global Assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>skin roughness improvement</measure>
    <time_frame>two weeks, 4 weeks and 8 weeks of treatment</time_frame>
    <description>To evaluate the improvement of the skin roughness after 2, 4 and 8 weeks of treatment.through the Investigator Global Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>skin texture improvement</measure>
    <time_frame>two weeks, 4 weeks and 8 weeks of treatment</time_frame>
    <description>To evaluate the change in skin texture after 2, 4 and 8 weeks of treatment, through the Investigator Global Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment compliance</measure>
    <time_frame>8 weeks</time_frame>
    <description>To evaluate the subject's adherence to treatment by the product accountability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject and Investigator Global Evaluation of Performance</measure>
    <time_frame>8 weeks of treatment</time_frame>
    <description>To evaluate the subject's and Investigator's global evaluation of satisfaction with regards to the performance of PAPIX ACNE SCAR through a specific questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment acceptability</measure>
    <time_frame>8 weeks of treatment</time_frame>
    <description>To evaluate the subject's overall acceptability of the treatment through a specific questionnaire.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>adverse event collection</measure>
    <time_frame>two weeks, 4 weeks and 8 weeks of treatment</time_frame>
    <description>To evaluate the local and general tolerability of PAPIX ACNE SCAR.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Acne</condition>
  <condition>Scars</condition>
  <arm_group>
    <arm_group_label>Papix acne scar</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Papix acne scar gel for 8 consecutive weeks, 2 times per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Papix acne scar</intervention_name>
    <description>PapiX acne scar, class IIa medical device, gel for acne scar. to be applied 2 times per day during the 8 weeks of study duration</description>
    <arm_group_label>Papix acne scar</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject's or parents or guardian (depending on the age of the subject) written&#xD;
             informed consent obtained prior to any study-related procedures;&#xD;
&#xD;
          2. Male or female subjects aged â‰¥ 12 years of any race;&#xD;
&#xD;
          3. Subjects with any Fitzpatrick skin phototype;&#xD;
&#xD;
          4. Subjects with clinical diagnosis of mild to moderate acne vulgaris (IGA score 2 or 3)&#xD;
             on the face;&#xD;
&#xD;
          5. Presence of acne scars (all types included), of grade mild or moderate according to&#xD;
             SGA;&#xD;
&#xD;
          6. Subjects with cooperative attitude, able to comprehend the full nature and the purpose&#xD;
             of the investigation, including possible risks and side effects, and able to comply&#xD;
             with the requirements of the entire investigation (including ability to attend the&#xD;
             planned visits according to the time limits), based on Investigator's judgement.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant women&#xD;
&#xD;
          2. Severe acne at inclusion or any acne requiring systemic treatment;&#xD;
&#xD;
          3. Presence of facial warts or fungal infections;&#xD;
&#xD;
          4. Active dermatitis on the face, rosacea, active herpes simplex;&#xD;
&#xD;
          5. Keloids presence in the area to be treated or keloids development during the treatment&#xD;
             period;&#xD;
&#xD;
          6. History of radiation or skin tumors in the/close to the area to be treated in the past&#xD;
             5 years;&#xD;
&#xD;
          7. Laser ablative procedures within the last month;&#xD;
&#xD;
          8. Chemical peels within the last 6 months;&#xD;
&#xD;
          9. Use of topical treatments like antibiotics, corticosteroids, benzoyl peroxide, azelaic&#xD;
             acid, hydroxy acids and other antinflammatory drugs within 2 weeks;&#xD;
&#xD;
         10. Use of topical retinoids within 4 weeks;&#xD;
&#xD;
         11. Use of systemic corticosteroids or antibiotics in the previous 30 days;&#xD;
&#xD;
         12. Use of systemic spironolactone/drospirenone or immunomodulators in the previous 3&#xD;
             months;&#xD;
&#xD;
         13. Use of oral retinoids or cyproterone acetate/chlormadinone acetate in the previous 6&#xD;
             months;&#xD;
&#xD;
         14. Use of scrub, alpha hydroxy acid (AHA), skin irritant products in the 2 days before&#xD;
             study treatment start;&#xD;
&#xD;
         15. Subjects with any other clinically significant or unstable concurrent disease or skin&#xD;
             condition or general condition that, in the Investigator's opinion, might interfere&#xD;
             with the study evaluations;&#xD;
&#xD;
         16. Allergy, sensitivity or intolerance to the components of the investigational device&#xD;
             formulations ingredients;&#xD;
&#xD;
         17. Concomitant or previous participation in other interventional clinical study in the&#xD;
             past 3 months;&#xD;
&#xD;
         18. Subjects planning sun exposure or tanning booths or UV sources throughout the course&#xD;
             of the study. In case of sun exposure this shall be limited and a protection cream&#xD;
             (SPF 50+) shall be applied.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aurora Parodi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale Policlinico San Martino, Genova</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aurora Parodi, MD</last_name>
    <phone>0105552783</phone>
    <email>aurora.parodi@hsanmartino.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ospedale San Martino</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aurora Parodi, MD</last_name>
      <phone>0105555750</phone>
      <email>aurora.parodi@hsanmartino.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 13, 2020</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2021</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cream</keyword>
  <keyword>mild moderate acne</keyword>
  <keyword>Papix</keyword>
  <keyword>Papix acne scar</keyword>
  <keyword>acne treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

